MetaVia (MTVA) announced dosing of the first patient in the 48 mg, multiple ascending dose, MAD, cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin, OXM, analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, GCGR, for the treatment of obesity. Top-line data is expected in the fourth quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTVA: